“If Rem-L really can show the benefits listed in the previous paragraph I believe there is no chance that the FDA could brush them aside. They could argue all they like about unknown mode of action, manufacturing issues and all the other theoretical objections in their briefing notes for the sr acuteGvHD ODAC meeting but they wouldn't be arguing with the team from MSB. They'd be up against tens of thousands of health workers, numerous politicians, millions of citizens. Their opinion would be irrelevant if enough people are convinced by results.”
you suggest that the FDA is obfuscating a company for little reason. That’s textbook conspiracy theory BS. Get off it.
trial was halted for futility. Novartis has extended cooling off period. The trial was started on some secondary endpoint from a 2015 COPD trial Mesoblast considered such a failure the indication isn’t even listed on their own website let alone that trials results. Look it up.
Every single trial has failed in Mesoblasts history. You can’t argue with that. Yet, seemingly, you want to.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-8034
-
- There are more pages in this discussion • 10,023 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 24054 | 0.935 |
8 | 131583 | 0.930 |
4 | 65851 | 0.925 |
7 | 113334 | 0.920 |
9 | 97006 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 1100 | 1 |
0.950 | 19026 | 2 |
0.955 | 27000 | 2 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online